Clinical trials: Systemic Embolism
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Atherosclerosis, Thromboembolism
Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
- Conditions
- Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus
- Trial name
- NCT00371501
- Testing
- Rosuvastatin, aspirin
- Where
- Hong Kong
- Volunteers
- 72 people
- Sponsor
- Tuen Mun Hospital
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke
This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with…
- Conditions
- Atrial Fibrillation, Stroke, Systemic Embolism
- Trial name
- 5A (NCT02478294)
- Testing
- Thoracoscopic LAA Excision plus AF Ablation, Warfarin or Novel Oral Anticoagulants
- Where
- China
- Volunteers
- 474 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pulmonary Embolism Acute
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
High-risk pulmonary embolism is a life-threatening condition requiring immediate reperfusion therapy. Full-dose systemic thrombolysis is recommended as first-line treatment, but its use is limited by the risk of major bleeding…
- Trial name
- REDSTEM (NCT07816978)
- Testing
- Reduced-dose alteplase, Full-dose alteplase
- Where
- 23 sites in Denmark, Norway and 1 more
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Raynaud's Phenomenon, Digital Ulcers
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life.
- Conditions
- Raynaud's Phenomenon, Digital Ulcers, Scleroderma
- Trial name
- NCT01117298
- Testing
- Tadalafil
- Where
- 4 sites in India
- Volunteers
- 66 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Atrial Fibrillation
The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
The purpose of this trial is to demonstrate the efficacy and safety of dabigatran etexilate and different intensity warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Trial name
- NCT02646267
- Testing
- standard intensity warfarin, low intensity warfarin, dabigatran etexilate
- Where
- China
- Volunteers
- 210 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital
Deep Vein Thrombosis
Coagulation Changes in Trauma Patients
Hypothesis to be tested: placement of a central venous catheter will induce a systemic hypercoagulable state. To determine this, the investigators will measure thromboelastography (TEG), PT(prothrombin time), PTT (partial…
- Trial name
- NCT00795743
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Postpartum Hemorrhage, Systemic Autoimmune Diseases
Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage
Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women.
- Trial name
- NCT06754371
- Testing
- tranexamic acid, normal saline
- Where
- China
- Volunteers
- 276 people
- Sponsor
- RenJi Hospital
Atrial Fibrillation, Stroke, Ischemic
The Fourth Left Atrial Appendage Occlusion Study
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving…
- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
- Trial name
- LAAOS-4 (NCT05963698)
- Testing
- WATCHMAN device
- Where
- 150 sites in United States, Belgium and 10 more
- Volunteers
- 4,000 people
- Sponsor
- Hamilton Health Sciences Corporation
Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-ATLAS (NCT07175428)
- Testing
- REGN7508, REGN9933, Apixaban
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Regeneron Pharmaceuticals
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
CREST Syndrome, Peripheral Vascular Disease
Exparel as a Nerve Block for Severe Hand Pain
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Trial name
- NCT02374320
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jose Soberon, MD
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Stroke
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
- Trial name
- WAVECREST2 (NCT03302494)
- Testing
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Where
- 25 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- Coherex Medical